Literature DB >> 23206493

Could low dead-space syringes really reduce HIV transmission to low levels?

P Vickerman1, N K Martin, M Hickman.   

Abstract

Studies published by Zule and colleagues have suggested that use of low dead-space syringes (LDSS) instead of high dead-space syringes (HDSS) by injecting drug users (IDUs) could dramatically reduce HIV transmission. However, evidence is limited because experiments have considered a small range of syringe types and have been unable to reliably estimate the efficacy of using LDSS for reducing HIV transmission. We critically appraise available evidence to determine whether using LDSS is likely to dramatically reduce HIV transmission. We systematically review the literature on the dead-space volume of syringes and estimate the factor difference in blood volume transferred from sharing LDSS or HDSS. Existing data on the relationship between host viral load and HIV transmission risk is used to evaluate the likely efficacy of using LDSS instead of HDSS. An HIV transmission model is used to make conservative impact projections for switching to using LDSS, and explore the implications of heterogeneity in IDU transmission risk and syringe preferences. Although highly variable, reviewed studies suggest that HDSS have on average 10 times the dead-space volume of LDSS and could result in 6/54/489 times more blood being transferred after 0/1/2 water rinses. Assuming a conservative 2-fold increase in HIV transmission risk per 10-fold increase in infected blood inoculum, HDSS use could be associated with a mean 1.7/3.6/6.5-fold increase in transmission risk compared to LDSS for 0/1/2 rinses. However, even for a low efficacy estimate, modelling suggests that partially transferring to LDSS use from using HDSS could dramatically reduce HIV prevalence (generally >33% if LDSS use is 50%), but impact will depend on IDU behavioural heterogeneity and syringe preference. Indirect evidence suggests that encouraging HDSS users to use LDSS could be a powerful HIV prevention strategy. There is an urgent need to evaluate the real life effectiveness of this strategy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23206493     DOI: 10.1016/j.drugpo.2012.10.006

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  12 in total

1.  Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City.

Authors:  Pedro Mateu-Gelabert; Honoria Guarino; Lauren Jessell; Anastasia Teper
Journal:  J Subst Abuse Treat       Date:  2014-07-11

2.  Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.

Authors:  Elizabeth Hancock; Zoe Ward; Rachel Ayres; Jane Neale; Deborah Hussey; Joanna May Kesten; Matthew Hickman; Peter Vickerman
Journal:  Addiction       Date:  2019-11-19       Impact factor: 6.526

3.  Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; David Goldberg; Norah Palmateer; Alison Munro; Avril Taylor; Matthew Hickman; Sharon Hutchinson; Peter Vickerman
Journal:  Addiction       Date:  2018-07-10       Impact factor: 6.526

4.  Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: A 24-month retrospective analysis of a nationally representative sample.

Authors:  Thai Hoang; Hong Nguyen; Ray W Shiraishi; Mai Nguyen; Trista Bingham; Diep Nguyen; Tam Nguyen; Hao Duong; Sheryl Lyss; Hien Tran
Journal:  Int J Drug Policy       Date:  2018-03-20

5.  Event-level analyses of sex-risk and injection-risk behaviors among nonmedical prescription opioid users.

Authors:  William A Zule; Christine Oramasionwu; Donna Evon; Sayaka Hino; Irene A Doherty; Georgiy V Bobashev; Wendee M Wechsberg
Journal:  Am J Drug Alcohol Abuse       Date:  2016-06-10       Impact factor: 3.829

6.  Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK.

Authors:  Adam Trickey; Margaret T May; Vivian Hope; Zoe Ward; Monica Desai; Ellen Heinsbroek; Matthew Hickman; Peter Vickerman
Journal:  Drug Alcohol Depend       Date:  2018-09-15       Impact factor: 4.492

7.  Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Authors:  Marian Major; Alexander Gutfraind; Louis Shekhtman; Qingwen Cui; Alla Kachko; Scott J Cotler; Behzad Hajarizadeh; Rachel Sacks-Davis; Kimberly Page; Basmattee Boodram; Harel Dahari
Journal:  Sci Transl Med       Date:  2018-07-11       Impact factor: 17.956

8.  Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England.

Authors:  Joanna M Kesten; Rachel Ayres; Jane Neale; Jody Clark; Peter Vickerman; Matthew Hickman; Sabi Redwood
Journal:  Int J Drug Policy       Date:  2016-10-24

9.  Social marketing of low dead space syringes in Vietnam: findings from a 1-year pilot program in Hanoi, Thai Nguyen, and Ho Chi Minh City.

Authors:  Ngo Thi Thanh Huong; Gary Mundy; Josselyn Neukom; William Zule; Nguyen Minh Tuan; Nguyen Minh Tam
Journal:  Harm Reduct J       Date:  2015-05-30

10.  Factors that influence the characteristics of needles and syringes used by people who inject drugs in Tajikistan.

Authors:  William A Zule; Alisher Latypov; David Otiashvili; Irma Kirtadze; Umedjon Ibragimov; Georgiy V Bobashev
Journal:  Harm Reduct J       Date:  2015-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.